Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Contemporary adverse event profile of microsurgery for intracranial unruptured aneurysms in high-volume microsurgical centers: the international PRAEMIUM study
Adamides, Alexios A. , Başkaya, Mustafa K. , Ieva, Antonio Di , Lawton, Michael T., Pinna, Giampietro, Podlesek, Dino , Radovanovic, Ivan, Rohde, Veit, Stroh-Holly, Nico , Sturiale, Carmelo Lucio, _, _, Fierstra, Jorn , Laidlaw, John D., Evans, Lachlan R. , Sayyahmelli, Sara, Sayyahmelli, Sima , Štekláčová, Anna , Morgan, Michael K. , Acerbi, Francesco , Oushy, Soliman , Rinaldo, Lorenzo , Thomé, Claudius , Geiger, Philipp , Musumeci, Angelo , Schackert, Gabriele , Bervini, David , Raabe, Andreas, Mansur, Ann , Olijnyk, Leonardo, Malinova, Vesna , Mielke, Dorothée , Gmeiner, Matthias , Gruber, Andreas , Kondajji, and Aditya M., Oushy, Soliman H , Bervini, David , Staartjes, Victor E. , Anania, Pasquale , Beneš, Vladimír , Dehdashti, Amir R. , Ferroli, Paolo , Jakola, Asgeir Store , Lanzino, Giuseppe , Lawton, Michael T. , Petr, Ondra , Petutschnigg, Thomas , Rohde, Veit , Sturiale, Carmelo Lucio , Wang, Anthony , Regli, Luca , Esposito, Giuseppe, _, _, Serra, Carlo , Sebök, Martina , Germans, Menno Robbert , Zona, Gianluigi , Fiaschi, Pietro , Yang, Kaiyun , Acerbi, Francesco , Vetrano, Ignazio G. , Klurfan, Paula , Catapano, Joshua S , Meneghelli, Pietro , Goldberg, Johannes , Gruber, Andreas, Auricchio, Annamaria , Olivi, Alessandro , Colby, Geoffrey P.

Mayo Clinic

Neurosurgical Focus | December 1, 2025 | Volume: 59 | Issue: 6 | Pages: E18

10.3171/2025.9.focus25723 | PMID 41343785 Get It

OBJECTIVE Objective values on procedural risk are essential to facilitate informed consent and optimize clinical decision-making in patients with unruptured intracranial aneurysms (UIAs). While robust heuristics, such as the PHASES (population, hypertension, age, size of aneurysm, earlier subarachnoid hemorrhage, and site of aneurysm) score, are established for predicting rupture risk, contemporary and granular benchmarks for procedural safety remain scarce. The multinational Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) study aims to comprehensively characterize contemporary adverse event rates following microsurgical treatment at high-volume expert centers, stratified by aneurysm location, morphology, and complexity factors to better inform individual risk/benefit analyses. METHODS A cohort study among 20 participating expert centers from 9 countries was established. Patients treated microsurgically for UIAs were included. The authors describe the epidemiology of treated patients and UIAs and a comprehensive adverse event profile using 3 outcomes measured at hospital discharge: 1) poor neurological outcome (modified Rankin Scale score ≥ 3), 2) new sensorimotor neurological deficits, and 3) all-cause adverse events (Clavien-Dindo grade ≥ 1). Subgroup reports were given for aneurysm location, morphology, and complexity factors (prior aneurysm treatment, calcifications, complex angioanatomy involving critical branch vessels or perforators, and thrombosis). The authors purposely chose discharge as the time point to capture early postoperative risks and complications in patients with asymptomatic UIAs, for whom preserving neurological function is paramount. RESULTS The cohort included 3705 patients (mean age 56 [SD 12] years, 28% male). Overall, at discharge 13.9% of patients (95% CI 12.8%–15.0%) had poor neurological functional outcomes, 14.4% (95% CI 13.3%–15.5%) had new sensorimotor deficits, and 24.1% (95% CI 22.8%–25.5%) experienced all-cause adverse events. Poor neurological outcomes ranged from 8.5% (M1 aneurysms) to 37.4% (posterior circulation aneurysms), neurological deficits from 9.3% (distal anterior cerebral artery [ACA] aneurysms) to 34.2% (posterior circulation aneurysms), and all-cause adverse events from 21.2% (distal ACA aneurysms) to 31.3% (posterior circulation aneurysms). Dissecting and fusiform aneurysms showed notably high rates of poor neurological outcomes (22.0%–33.3%), new deficits (25.4%–26.7%), and adverse events (26.7%–37.0%). Complexity factors significantly influenced outcomes, with prior treatment (22.9%, 19.7%, and 30.1%), calcification (16.3%, 18.1%, and 30.5%), complex angioanatomy (13.1%, 15.9%, and 26.9%), and thrombosis (19.6%, 23.9%, and 39.6%) notably increasing the risks for poor neurological outcomes, deficits, and adverse events, respectively. CONCLUSIONS This large international cohort provides contemporary benchmarks for microsurgical treatment of UIAs, emphasizing variability in outcomes based on aneurysm location, morphology, and complexity. The presented granular and quotable adverse event rates support informed patient counseling and individualized risk/benefit assessments in comparable high-volume centers.
Patient Awareness of Alcohol Consumption and Breast Cancer Risk
Mussallem, Dawn M. , Farkouh, Elizabeth K. , Smith, Taryn , Smith, Taryn L., Farkouh, E K , Wang, Jing

Mayo Clinic

American Journal of Lifestyle Medicine | November 29, 2025 | Volume: 20 | Issue: 3 | Pages: 418-431

10.1177/15598276251401194 | PMID 41328320 Get It

Objective To estimate the proportion of female patients from Mayo Clinic Family Medicine and Community Internal Medicine clinics who are aware of alcohol use as a breast cancer (BC) risk factor. Patients and Methods One thousand women aged 21 to 70 completed a survey collecting information on demographics, medical/family history, frequency and quantity of alcohol consumption, and other health behaviors. Participants were also asked to grade how likely certain factors were to increase lifetime BC risk. Results Most participants (844/990 [85.3%]) identified a family history of BC as a BC risk factor. In contrast, 48.4% (475/982) identified alcohol use as a BC risk factor. The remaining 51.6% (507/982) reported either they were not sure about alcohol consumption as a risk factor (341/982 [34.7%]), believed that there was no association (143/982 [14.6%]), or believed that alcohol consumption decreases the risk of BC (23/982 [2.3%]). In multivariable analyses, factors associated with awareness of alcohol consumption and BC risk included having never been pregnant ( P = 0.048), more education ( P < 0.001), and higher frequency of alcohol consumption in the past 12 months ( P = 0.005). Conclusion Further education of patients and the public is needed to promote awareness of alcohol as a risk factor for BC.
Tissue Microarray-Based Digital Spatial Profiling of Benign Breast Lobules and Breast Cancers: Feasibility, Biological Coherence, and Cross-Platform Benchmarks
Carter, Jodi C., Vierkant, Robert A. , Pacheco-Spann, Laura M. , Vachon, Celine M. , Jensen, Matthew R. , Thompson, E. Aubrey , Kachergus, Jennifer M., Shi, Ji , Radisky, Derek C. , Vierkant, Robert A , Stallings-Mann, Melody, Pacheco-Spann, Laura M , Kachergus, Jennifer, Shi, Ji , Radisky, Derek C , Sherman, Mark E. , Carter, Jodi C., Stallings‐Mann, Melody , Winham, Stacey J. , Vachon, Celine M. , Wang, Chen , Troester, Melissa A. , Degnim, Amy C.

Mayo Clinic

Cancers | November 27, 2025 | Volume: 17 | Issue: 23 | Pages: 3797

10.3390/cancers17233797 | PMID 41374998 Get It

Background: Discovering risk biomarkers in small benign breast disease (BBD) biopsies is constrained by scarce tissue and microanatomic heterogeneity of terminal duct lobular units (TDLUs). We tested whether tissue-sparing tissue microarray (TMA)–based Digital Spatial Profiling (DSP) can deliver reproducible, biologically coherent protein measurements across benign lobules and breast cancers (BCs), and how well DSP aligns with standard immunoassays. Methods: We performed a pilot using tissues from the Mayo Clinic BBD cohort using TMAs representing four contexts: terminal duct lobular units (TDLUs) from BBD biopsies preceding BC and matched BBD-controls, subsequent BCs, and BC-associated TDLUs. We profiled 79 proteins by DSP (37 retained after QC) and benchmarked against chromogenic IHC and OPAL immunofluorescence. Reproducibility was evaluated using intraclass correlation coefficients (ICCs), cross-platform agreement (weighted kappa), marker correlations, and mixed-effects models with false-discovery-rate (FDR) control. Results: We analyzed 368 BBD-TDLU cores (88 cases; 88 controls), 204 BC cores and 110 BC-associated TDLU cores. ICCs were highest in BC tissues, and lower in BC-associated TDLUs and BBD-TDLUs. Agreement was slight–to-fair in TDLUs but moderate (ER/PR) to substantial (BCL2) in BC. DSP recapitulated expected immunologic correlations (CD45 with T-cell, B-cell, and macrophage markers) and tissue-type gradients (BC > BC-associated TDLUs > BBD-TDLUs). Exploratory case–control differences in BBD-TDLUs did not persist after FDR control. Conclusions: TMA-based DSP is feasible in archival breast tissues and yields biologically coherent, cross-platform-benchmarked profiles that are particularly robust in BC, while conserving scarce TDLUS and clarifying current limits of single-marker risk stratification from benign lobules. These data provide a foundation for refined sampling and expanded panels in future TDLU-focused studies.
FSTL1 Orchestrates Metabolic‐Epigenetic Crosstalk: Glycolysis‐Dependent H3K18 Lactylation Drives Cartilage Fibrosis in Osteoarthritis
Lu, Feng , Yu, Yunyuan , Yin, Guangrong , Hu, Huiqun, Li, Shishuo , Tang, Yuting , Liu, Yimin , Li, Maoyuan, Wang, Liang , Zhao, Gongyin , Zhou, Baojun , Wang, Yuji , Wang, Yuji , Liu, Yimin, Wang, Liang liang, Xu, Chao

Mayo Clinic

Advanced Science | November 26, 2025 | Volume: 13 | Issue: 8 | Pages: No page available

10.1002/advs.202512002 | PMID 41293926 Get It

Abstract The progression of osteoarthritis (OA) is fundamentally characterized by the aberrant transformation of chondrocytes into a fibrotic phenotype, although the precise molecular mechanisms involved remain inadequately understood. In this study, the interplay between epigenetic modifications and metabolic reprogramming during the activation of fibrocartilage cells in osteoarthritis was investigated. The findings demonstrate that FSTL1 markedly upregulates key glycolytic enzymes, including LDHA, HK2, and PKM, in chondrocytes, triggering a “glycolytic burst” that results in elevated intracellular lactate levels. This accumulated lactate acts as a precursor for epigenetic modifications, specifically promoting the lactylation of histone H3 lysine 18 (H3K18la) in fibrocartilage cells, thereby facilitating the transcriptional activation of critical fibrosis‐related genes such as Itga6, Cxcl10, and Parp16. Notably, pharmacological inhibition of the PI3K/mTOR pathway or lactate dehydrogenase significantly diminishes H3K18la levels and markers of chondrocyte fibrosis, while exogenous lactate supplementation can counteract this effect. In summary, this study unveils the core mechanism by which FSTL1 reshapes the epigenetic landscape of chondrocytes and drives the fibrotic process through the activation of the “glycolysis‐lactate‐H3K18la” cascade axis, offering a dual‐target intervention strategy for OA involving metabolic reprogramming and epigenetic modification.
CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement
Li, Hao , Luo, Jindan , Liang, Huaiyuan , Yanfeng, Bai , Liu, Jiandong , Wei, Ting , Wang, Liguo , Guo, Hongshan , Xia, Dan , Huang, Haojie , Sun, Rui , Bai, Yanfeng , Wang, Liguo , Huang, Rui , Wei, Ting , Liu, Jiandong , Sun, Rui

Mayo Clinic

Cancer Research | November 25, 2025 | Volume: 86 | Issue: 5 | Pages: 1180-1193

10.1158/0008-5472.can-25-1761 | PMID 41289556 Get It

Abstract CDK12 is frequently deleted and/or mutated in human cancers, and CDK12 inactivation is associated with aggressive phenotypes, including the tendency to metastasis. In this study, we showed that CDK12 deficiency induced intronic polyadenylation (IPA) usage in BRD4 to upregulate expression of the bromodomain-containing protein 4 (BRD4) short isoform (BRD4S). BRD4S demonstrated an enhanced capacity to form phase separation despite lacking the intrinsically disordered region located in the C-terminal of full-length BRD4. Oligomerization of BRD4S mediated phase separation through a base-interacting structural domain. CUT&Tag and RNA sequencing analyses revealed that BRD4S preferentially bound to the promoters of TGFβ signaling genes, including TGFB2 and LTBP1, driving their expression. Consistently, BRD4S drove cancer cell dissemination in vitro and metastasis in vivo, which could be blocked by BET or TGFβ signaling pathway inhibitors. Overall, this study identifies IPA usage at the BRD4 gene locus induced by CDK12 deficiency as a mechanism responsible for BRD4S genesis, which represents an important mechanism driving cancer metastasis and a potential target for therapeutic intervention in CDK12-deficient cancers. Significance: The CDK12–BRD4S–TGFβ signaling axis represents a key regulatory module that promotes metastatic progression and can be targeted by BET or TGFβ pathway inhibitors for treating CDK12-deficient cancers.
A Ciliary Phosphoinositide Pathway Regulates the Dosage of Polycystins in Primary Cilia
Wang, Zhifei , Ellis, Madilyn R. , Ji, Biyun , Sieben, Cynthia J. , Haycraft, Courtney J. , Croyle, Mandy J. , Aghevli, Ariana, Xu, Qingwen , Robichaud, Jielu Hao, Huang, Yan , Yoder, Bradley K. , Hu, Jinghua , Yu, Yong , Ling, Kun , Chen, Chuan , Wang, Zhifei , Gao, Yue, Ellis, Madilyn R , Ji, Biyun , Sieben, Cynthia J , Croyle, Mandy , Xu, Qingwen , Robichaud, Jielu H, He, Kai , Huang, Yan , Yoder, Bradley K , Harris, Peter C , Yu, Yong , Ling, Kun , Chen, Chuan , Gao, Yue , Hao, Jielu , He, Kai , Chen, Chunhua , Harris, Peter C.

Mayo Clinic

Journal of the American Society of Nephrology | November 25, 2025 | Volume: 37 | Issue: 5 | Pages: 944-958

10.1681/asn.0000000942 | PMID 41563398 Get It

Key Points Inositol polyphosphate-5-phosphatase E (INPP5E) and type Ig phosphatidylinositol-4-phosphate 5-kinase (PIPKIγ) coordinated the homeostasis of phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate in primary cilia. Modulating INPP5E or PIPKIγ activity changed the level of polycystin-1 and polycystin-2 in primary cilia. INPP5E inhibition increased the hypomorphic PKD1 variants (PC1-R3277C) in cilia and reduced cystogenesis in the kidney in vitro . Background Autosomal dominant polycystic kidney disease is mainly caused by mutations in PKD1 and PKD2 , which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 and PC2 assemble a cation channel complex enriched in primary cilium, a sensory organelle associated with various developmental diseases, including polycystic kidney disease (PKD). Accumulating evidence supports the necessity of functional polycystin (PC) complex in cilia to prevent cystogenesis in the kidney, indicating that improving their ciliary levels may ameliorate defects underlying PKD pathogenesis. Yet, molecular mechanisms underlying the ciliary targeting and homeostasis of the PC complex are not fully understood. Methods Indirect immunofluorescence microscopy was used to monitor ciliary levels of PC1 and PC2 in renal epithelial cells. Electrophysiology analysis in oocytes was used to determine the channel activity of the PC complex. Cystogenesis in the kidney was measured using in vitro 3D-Matrigel cell models and ex vivo mouse embryonic kidney models. Results Suppressing inositol polyphosphate-5-phosphatase E (INPP5E) or activating type Ig phosphatidylinositol-4-phosphate 5-kinase raised ciliary levels of the PC complex in both normal renal epithelial cells and cells carrying autosomal dominant polycystic kidney disease mutations that interrupt the trafficking of PCs into cilia, including GANAB inactivation and the trafficking PKD1 mutation p.Arg3277Cys (RC). PC1 RC formed a complex with PC2 and exhibited normal channel activity in vitro . An INPP5E that increases PC1 and PC2 in cilia, suppressed in vitro forskolin-induced cystogenesis of inner medullary collecting duct epithelial cell line 3 cells in 3D Matrigel and ex vivo cyst formation in embryonic Pkd1 RC/RC mouse kidneys. Conclusions Our results demonstrated that increasing the ciliary level of PCs, by manipulating a ciliary phosphoinositide signaling axis, enhanced the functionality of PCs and suppressed cystogenesis of renal epithelial cells in vitro .
Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy
Schultz, Sydney , Barreto, Jason N. , Cole, Kristin C., Wang, Yucai , Choong, Grace M. , Leung, Nelson , Schultz, Sydney E , Leung, Nelson , Wang, Yucai , Choong, Grace M , Cole, Kristin C.

Mayo Clinic

JCO Oncology Practice | November 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-00543 | PMID 41270242 Get It

PURPOSE The difference in time to serum calcium normalization and rates of subsequent refractory hypocalcemia between bisphosphonates requires further investigation. Our primary objective was to assess the difference in normalization of serum calcium between pamidronate and zoledronic acid during treatment of hypercalcemia of malignancy (HCM) and rates of subsequent, refractory hypocalcemia following therapy. METHODS A retrospective review of patients with cancer who received pamidronate or zoledronic acid inpatient at Mayo Clinic for treatment of HCM between January 2018 and January 2024 was conducted. Logistic regression evaluated the association between treatment groups and outcomes. Multivariable modeling was adjusted for baseline differences, including severity of hypercalcemia. RESULTS We evaluated 856 patients. The median age was 68 (IQR, 59-75) years, and 476 (55.6%) were male. The most common cancer diagnoses were lymphoma (n = 158, 18.5%), followed by multiple myeloma (n = 145, 16.9%) and lung cancer (n = 111, 13%). Overall, 292 (46.8%) patients and 154 (32.8%) patients achieved serum calcium normalization by hospital day 4 and day 7, respectively. The rate of normalization was similar between all bisphosphonates, regardless of pamidronate dose. Significantly higher rates of hypocalcemia were observed on day 4 for patients who received zoledronic acid 4 mg once compared with either dose (60 mg once and 90 mg once) of pamidronate (40.7% v 27.6% v 26.8%, P = .049, respectively). No significant difference in rates of hypocalcemia were observed on day 7 (56.8% v 50% v 42.9%, P = .26, respectively) and day 30 (39.1% v 39.0% v 37.5%, P = .50, respectively). CONCLUSION Bisphosphonates were equally efficacious in normalizing serum calcium in patients with HCM. Pamidronate 90 mg was not more efficacious than 60 mg. Rates of refractory hypocalcemia were similar.
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma
Phillips, Tycel , Di, Mengyang , Miller, Taavy A. , Wang, Jingru , Pierre, Amy , Maglinte, Gregory A. , Wang, Yucai , Wang, Yucai , Phillips, Tycel , Di, Mengyang , Seymour, Erlene Kuizon

Mayo Clinic

Blood Advances | November 21, 2025 | Volume: 10 | Issue: 5 | Pages: 1457-1468

10.1182/bloodadvances.2025017160 | PMID 41269777 Get It

Abstract This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed/refractory mantle cell lymphoma (R/R MCL) from electronic health records in the United States. Adults with R/R MCL who received second- or third-line (2L/3L) zanubrutinib, acalabrutinib, or ibrutinib monotherapy, on or after 1 January 2018, were included. Inverse probability of treatment weighting was used in adjusted Cox models to compare real-world time-to-next treatment (rwTTNT) and overall survival (rwOS). Among 698 patients who received 2L/3L cBTKi monotherapy, 49%, 32%, and 19% received acalabrutinib, ibrutinib, and zanubrutinib, respectively. Unadjusted analyses showed median rwTTNT for 2L zanubrutinib, acalabrutinib, and ibrutinib was 14.5 (95% confidence interval [CI], 11.0-23.2), 12.8 (95% CI, 10.5-15.6), and 10.3 (95% CI, 7.6-13.7) months, and median rwOS was 26.4 (95% CI, 23.2 to not reached [NR]), 29.2 (95% CI, 22.9-38.1), and 29.3 (95% CI, 21.8-41.6) months, respectively. Median rwTTNT for 3L zanubrutinib, acalabrutinib, and ibrutinib was 21.1 (95% CI, 3.9 to NR), 9.2 (95% CI, 6.8-14.7), and 9.6 (95% CI, 4.8-18.0) months, and median rwOS was NR (95% CI, 27.3 to NR), 27.4 (95% CI, 15.1-42.2), and 27.0 (95% CI, 15.6 to NR) months, respectively. Adjusted models in the 2L/3L cohorts combined showed numerically longer rwTTNT and statistically significantly longer rwOS for zanubrutinib vs ibrutinib (hazard ratio, 0.63; 95% CI, 0.42-0.96), and trends for improved rwTTNT and rwOS for zanubrutinib over acalabrutinib. Toxicity was a frequent reason for changing to another cBTKi. These findings suggest potential improvements in rwTTNT and rwOS with the use of second- and next-generation cBTKis for R/R MCL from 2018 and beyond.
SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk
Moreno, Sira , Lenz, S., Casso-Chapa, Bernardo , Paniagua-Bojorges, Angelica , Kim, Jung Hyun , Palaskas, Nicolas L. , Nead, Kevin T. , Samanthapudi, Venkata Subrahman K, Mejia, Gilbert, Hoang, O.N. , Lee, Jonghae , Lin, Steven H. , Herrmann, Joerg , Yusuf, Syed Wamique , Iliescu, Cezar , Beinart, Noah , Manisty, Charlotte , Fukai, Tohru , Ameri, Pietro , Nurieva, Roza , Hildebrandt, Michelle A T, Schadler, Keri , Le, Nhat‐Tu , Abe, Jun‐ichi , López Moreno, Silvia Fernanda , Hoang, Oanh , Iliescu, Cezar A , Fukai, Tohru , Ameri, Pietro , Schadler, Keri , Le, Nhat-Tu , Abe, Jun-Ichi , Lin, Steven H , Palaskas, Nicolas L , Nead, Kevin T , Lee, Jonghae , Kim, Jung Hyun , Lenz, Stefania Assunto, Wang, Guangyu , Yusuf, Syed Wamique , Ushio‐Fukai, Masuko , Hildebrandt, Michelle A.T. , Koutroumpakis, Efstratios , Kotla, Sivareddy

Mayo Clinic

Antioxidants | November 21, 2025 | Volume: 14 | Issue: 12 | Pages: 1388

10.3390/antiox14121388 | PMID 41462587 Get It

Src homology 2-domain containing protein tyrosine phosphatase 2 (SHP2), encoded by the Ptpn11 gene (Tyrosine-protein phosphatase non-receptor type 11), is a key downstream effector of PD-1/PD-L1 signaling and is likely important, in addition to immune modulation, in tumor development and vascular homeostasis. SHP2 conveys PD-1 mediated inhibitory signaling in T cells, and is emerging as a therapeutic target. Importantly, there is an association between immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs), and cardiovascular complications, underscoring the need to understand SHP2’s role in these processes. This review aims to summarize current knowledge on SHP2/PTPN11 biology, its role in immune regulation, cancer progression, and vascular homeostasis, and to discuss emerging therapeutic strategies targeting this pathway. The concept of using SHP2 inhibitors with immune checkpoint inhibitors (ICIs) is being investigated to address ICI resistance and to improve anti-tumor efficacy substantially. SHP2 is also being studied in non-cancer cell contexts, and signaling responses can differ by large magnitudes depending on the biological context and stimuli. Under normal circumstances, SHP2 promotes vascular homeostasis in endothelial cells (ECs) and myeloid cells and inhibits inflammation, and the reduction in SHP2 activity by oxidative stress, such as in atherosclerosis or diabetes, upregulates inflammation. In contrast, in response to radiation, the fibrotic response and subsequent lung injury were increased by endothelial SHP2 induction via Notch-Jag1 signaling. Vascular smooth muscle cells SHP2 act as a pro-atherogenic effector by enhancing ERK/MAPK signaling, and the upregulation of mitochondria localized SHP2 can also induce cellular senescence-associated inflammation by upregulating mitochondrial reactive oxygen species. Taken together, the two opposite signaling effects of SHP2 suggest that both the immune and vascular system responses appear to be more modulated by the redox, cell, and compartment-specific signaling of SHP2. More studies are needed for mitigating cardiovascular toxicity to patients, particularly with ICI-based treatment regimens.
Modeling the acoustic profiles of vocal emotions in American English and Mandarin Chinese
Wang, Fenqi

Mayo Clinic

Phonetica | November 21, 2025 | Volume: 82 | Issue: 6 | Pages: 445-487

10.1515/phon-2025-0003 | PMID 41267336 Get It

Abstract This study examined the acoustic profiles of five basic emotions in American English and Mandarin Chinese using a big data approach. A total of 6,373 features were extracted using the openSMILE toolkit, and key discriminative features were identified through random forest classification. In American English, vocal emotions were primarily conveyed through pitch-related features, while Mandarin Chinese, shaped by its tonal constraints, relied more on spectral and voice quality cues, including MFCCs, HNR, and shimmer. Linear mixed-effects models confirmed significant effects of emotion on the top-ranked features, and Cohen’s d further supported distinct acoustic profiles for each emotion. K-means clustering revealed both categorical groupings and dimensional overlaps, such as the clustering of high-arousal emotions like happy and surprised, and low-arousal emotions like sad and neutral. These results suggest that vocal emotion expression is shaped by language-specific prosodic systems, as well as by both discrete emotion categories and continuous affective dimensions, supporting an integrated model of emotional prosody.